46182-58-5

Usage

Uses

Used in Pharmaceutical Industry:
C-(5-PHENYL-[1,3,4]OXADIAZOL-2-YL)-METHYLAMINE is used as a pharmaceutical agent for its potential anti-cancer properties. It is being studied for its ability to inhibit enzymes that play a role in cancer cell growth and proliferation, making it a promising candidate for the development of new cancer therapies.
Used in Medicinal Chemistry Research:
C-(5-PHENYL-[1,3,4]OXADIAZOL-2-YL)-METHYLAMINE is used as a research compound in medicinal chemistry. Its unique structure and potential biological activity make it a valuable tool for understanding the mechanisms of enzyme inhibition and the development of new drugs targeting various diseases, including cancer.
Used in Drug Development:
C-(5-PHENYL-[1,3,4]OXADIAZOL-2-YL)-METHYLAMINE is used in drug development as a lead compound for the design and synthesis of new pharmaceuticals. Its potent inhibitory effects on enzymes and potential anti-cancer properties make it a valuable starting point for the development of novel therapeutic agents.

InChI:InChI=1/C9H9N3O/c10-6-8-11-12-9(13-8)7-4-2-1-3-5-7/h1-5H,6,10H2

Upstream product

• 100-52-7 benzaldehyde 
• 934638-47-8 2-(azidomethyl)-5-phenyl-1,3,4-oxadiazole 
• 33575-83-6 2-(chloromethyl)-5-phenyl-1,3,4-oxadiazole 
• 613-94-5 benzoic acid hydrazide 
• 68496-63-9 5-phenyl-1,3,4-oxadiazole-2-carbonitrile 
• 1170-54-3 N'-benzoyl-2-benzyloxycarbonylamino-acetohydrazonic acid ethyl ester 

Downstream Products

• 1342816-74-3 2-cyanoethyl [(5-phenyl-1 ,3,4-oxadiazol-2-yl)methyl]dithiocarbamate 
• 486435-52-3 N-(5-phenyl-[1,3,4]oxadiazol-2-yl-methyl)-4-(4'-trifluoromethyl-biphenyl-2-carbonyl-amino)-1-methyl-pyrrole-2-carboxylic acid amide 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of nitrofuran-1,3,4-oxadiazole hybrids as new antitubercular agents

Three series of novel nitrofuran-1,3,4-oxadiazole hybrids were designed and synthesized as new anti-TB agents. The structure activity relationship study indicated that the linkers and the substituents on the oxadiazole moiety greatly influence the activity, and the substituted benzenes are more favoured than the cycloalkyl or heterocyclic groups. Besides, the optimal compound in series 2 was active against both MTB H37Rv strain and MDR-MTB 16883 clinical isolate and also displayed low cytotoxicity, low inhibition of hERG and good oral PK, indicating its promising potential to be a lead for further structural modifications.

Discovery of novel heteroarylmethylcarbamodithioates as potent anticancer agents: Synthesis, structure-activity relationship analysis and biological evaluation

A series of new analogs based on the structure of lead compound 10 were designed, synthesized and evaluated for their in vitro anti-cancer activities against four selected human cancer cell lines (HL-60, Bel-7402, SK-BR-3 and MDA-MB-468). Several synthesized compounds exhibited improved anti-cancer activities comparing with lead compound 10. Among them, 1,3,4-oxadiazole analogs 17o showed highest bioactivity with IC50 values of 1.23, 0.58 and 4.29 μM against Bel-7402, SK-BR-3 and MDA-MB-468 cells, respectively. It is noteworthy that 17o has potent anti-proliferation activity toward a panel of cancer cells with relatively less cytotoxicity to nonmalignant cells. The further mechanistic study showed that it induced apoptosis and cell cycle arrest through disrupting spindle assembly in mitotic progression, indicating these synthesized dithiocarbamates represented a novel series of anti-cancer compounds targeting mitosis.

INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS

The present invention relates to compounds of Formula I: I which are agonists of the M-1 muscarinic receptor.